<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893629</url>
  </required_header>
  <id_info>
    <org_study_id>UDMS-Cardio-01-2021</org_study_id>
    <nct_id>NCT04893629</nct_id>
  </id_info>
  <brief_title>New Horizons for the Treatment of Cardiomyopathy in Children</brief_title>
  <official_title>The Effectiveness of Autologous Mono Nuclear Cells in the Treatment of Dilated Cardiomyopathy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damascus University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damascus University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collecting mono nuclear cells from the patient's blood after a course of granulocyte&#xD;
      stimulation then injecting them into the weak heart muscle measuring the heart function at&#xD;
      the beginning and after 2.4.6 months to assess the improvement due to this procedure, by&#xD;
      comparing these patients to patients with the same condition treated the classic way.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dilated cardiomyopathy in children has high morbidity and mortality, current treatment&#xD;
      doesn't improve the prognosis and the only cure available is heart transplantation which is&#xD;
      limited, has long waiting list (if available), high cost, and has many side effects, leading&#xD;
      to the need of novel effective, less costly therapeutic alternatives.&#xD;
&#xD;
      Stem cell therapy has proven to improve the cardiac function, reverse the pathologic&#xD;
      histological changes, decrease the morbidity and mortality, offering a possible replacement&#xD;
      to heart transplantation, different reports proved the safety and efficacy of this therapy&#xD;
      using different types of cells and different routs of application in cardiomyopathy and acute&#xD;
      myocardial infarction in children and adults, and in congenital heart disease, but the&#xD;
      published cases of this therapy conducted on children with dilated cardiomyopathy are scanty&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricle ejection fraction (LVEF)</measure>
    <time_frame>6 months</time_frame>
    <description>measured by echo (mono mode, 3 Dimentional)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>children diagnosed with dilated cardiomyopathy , will undergo trans endocardium injection of mono nuclear cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>children diagnosed with dilated cardiomyopathy ,will continue the classic medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mono nuclear cells injection</intervention_name>
    <description>trans endocardium injection of autologous mono nuclear cells for the intervention group and classic treatment for the control group</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin+furosemide+captopril</intervention_name>
    <description>classical heart failure medical treatment</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>lasix,capoten</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dilated cardiomyopathy diagnosed and treated at least 6 mo. Ago&#xD;
&#xD;
          -  LVEF less than 40%&#xD;
&#xD;
          -  Use of I.V inotropes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  Severe organ failure (other than the heart)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>samir srour, prof</last_name>
    <role>Study Chair</role>
    <affiliation>membership of the French society of the pediatric cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>el-hindi</last_name>
    <phone>00963949185478</phone>
    <email>Sania.hindi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children'S Hospital</name>
      <address>
        <city>Damascus</city>
        <zip>011</zip>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sania el-hindi, MD</last_name>
      <phone>00963949185478</phone>
      <email>Sania.hindi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1186/s13287-019-1238-5</url>
    <description>-Wang et al. Stem Cell Research &amp; Therapy (2019) 10:137</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.21037/tp.2019.03.01</url>
    <description>I. M-Behnke et al. Regenerative therapies in young hearts with structural or congenital heart disease</description>
  </link>
  <reference>
    <citation>Selem SM, Kaushal S, Hare JM. Stem cell therapy for pediatric dilated cardiomyopathy. Curr Cardiol Rep. 2013 Jun;15(6):369. doi: 10.1007/s11886-013-0369-z. Review.</citation>
    <PMID>23666883</PMID>
  </reference>
  <reference>
    <citation>Zeinaloo A, Zanjani KS, Bagheri MM, Mohyeddin-Bonab M, Monajemzadeh M, Arjmandnia MH. Intracoronary administration of autologous mesenchymal stem cells in a critically ill patient with dilated cardiomyopathy. Pediatr Transplant. 2011 Dec;15(8):E183-6. doi: 10.1111/j.1399-3046.2010.01366.x. Epub 2010 Sep 29.</citation>
    <PMID>20880092</PMID>
  </reference>
  <reference>
    <citation>Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res. 2013 Jan 4;112(1):165-73. doi: 10.1161/CIRCRESAHA.112.276519. Epub 2012 Oct 12.</citation>
    <PMID>23065358</PMID>
  </reference>
  <reference>
    <citation>Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007 May 28;167(10):989-97. Review.</citation>
    <PMID>17533201</PMID>
  </reference>
  <reference>
    <citation>Mozid AM, Arnous S, Sammut EC, Mathur A. Stem cell therapy for heart diseases. Br Med Bull. 2011;98:143-59. doi: 10.1093/bmb/ldr014. Epub 2011 May 19. Review.</citation>
    <PMID>21596713</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dilated</keyword>
  <keyword>Cardio-myopathy</keyword>
  <keyword>pediatric</keyword>
  <keyword>mono</keyword>
  <keyword>nuclear</keyword>
  <keyword>cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

